Physician profile
Robert M Spear
NPI 1497783153
$3,591.29
in general payments reported to CMS, 2019-2025
24 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 84% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2021: $36.12 · 2022: $38.44 · 2023: $477 · 2024: $565 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Travel and Lodging: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.54 |
| Travel and Lodging | $850.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,184.12 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $803.23 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Medtronic USA, INC. | $448.04 | 2019 | |
| Lundbeck LLC | $139.80 | 2024-2025 | Vyepti |
| Globus Medical, INC. | $119.32 | 2025 | Senza |
| Bioventus LLC | $113.05 | 2019-2025 | Durolane, Xcell |
| Lilly USA, LLC | $104.79 | 2023-2025 | Emgality, Zepbound, Mounjaro |
| Merz Pharmaceuticals, LLC | $78.04 | 2023-2024 | Xeomin |
| Fidia Pharma USA INC. | $72.13 | 2019-2024 | Hymovis |
| Allergan, INC. | $57.08 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $52.61 | 2019 | |
| Curonix LLC | $46.42 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merz North America, INC. | $45.34 | 2019 | |
| Nevro Corp. | $44.01 | 2019-2023 | Senza |
| Azurity Pharmaceuticals, INC. | $41.36 | 2025 | Horizant |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $38.77 | 2023-2024 | Qutenza |
| Medtronic, INC. | $35.74 | 2025 | Intellis Adaptivestim |
| Vertex Pharmaceuticals Incorporated | $33.09 | 2025 | |
| Pacira Therapeutics, INC. | $27.73 | 2019 | |
| Electronic Waveform Lab, INC. | $27.42 | 2019 | |
| Fortis Surgical, LLC | $22.27 | 2025 | |
| Avanos Medical | $21.53 | 2023 | Coolief* Cooled Radiofrequency |
| Spr Therapeutics, INC | $21.11 | 2025 | Sprint Pns System |
| Biodelivery Sciences International, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.